TCGA-D8-A143-01A-11R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.640
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.470
- GLYCOLYSIS+0.430
- MTORC1_SIGNALING+0.380
- MITOTIC_SPINDLE+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- HYPOXIA+0.300
- MYC_TARGETS_V2+0.290
- SPERMATOGENESIS+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- ESTROGEN_RESPONSE_EARLY-0.360
- TGF_BETA_SIGNALING-0.270
- INTERFERON_GAMMA_RESPONSE-0.240
- UV_RESPONSE_DN-0.230
- BILE_ACID_METABOLISM-0.210
- COAGULATION-0.190
- ANGIOGENESIS-0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
- MYOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579844 | — | E | 0.849 |
| 2 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.848 |
| 3 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.837 |
| 4 | TCGA-D8-A1JM-01A-11R-A13Q-07 | — | E | 0.815 |
| 5 | TCGA-BH-A18T-01A-11R-A12D-07 | — | E | 0.809 |
| 6 | TCGA-A2-A0T0-01A-22R-A084-07 | — | E | 0.808 |
| 7 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.800 |
| 8 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.800 |
| 9 | TCGA-AN-A0G0-01A-11R-A034-07 | — | E | 0.797 |
| 10 | BSR_04_0077_A8_S97 | — | E | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.640 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |